





**Protective Effect of DPPC and P35 Against  
Challenge of Indomethacin (Indo, 40 mg/ kg) and  
Risedronate (100 mg/ kg) in Rats**



**Protective Effect of DPPC and P35 Against  
Challenge of Indomethacin (Indo, 40 mg/kg) and  
Risedronate (100 mg/kg) in Rats**

8-22-02 hg





## Bioavailability of Risedronate (Ris)<sup>α</sup> and PC-Risedronate (PC-Ris)<sup>β</sup> in Rats

	0.5 hour		1 hour		2 hour		4 hour		8 hour		24 hour	
	Ris	PC-Ris	Ris	PC-Ris	Ris	PC-Ris	Ris	PC-Ris	Ris	PC-Ris	Ris	PC-Ris
14863	23464	2678	14267	3062	1294	2733	2566	235	3287	73	85	
5529	2459	2660	10914	13952	14689	1162	2162	823	555	85	74	
4299	3354	17457	2632	1907	1599	777	1352	471	379	168	146	
16616	2347	5174	2348	7349	5972	1741	15557	466	621	78	226	
34649	8486	1714	3683	1057	6160	2326	7264	507	538			
1304	2636	1416	11137	983	7340	5110	2811	384	5210			
8011	1262	1283	2165	1347	1217	1639	2155	312	5987			
8733	-----	2085	860	1588	7168	2186	2453	366	1128			
11751	6287	4398	6001	3906	5684	2209	4540	446	2213*	101	133	
±3742	±2997	±1915	±1842	±1615	±1594	±471	±1698	±63	±813	±23	±35	

<sup>α</sup> Ris, at a specific activity of 100  $\mu\text{Ci}/\text{mg}$  was administered to fasted male Sprague Dawley rats (250-300g) at a final dose of 1 mg/kg (or  $\sim 65 \times 10^6$  cpm/rat).


<sup>β</sup> Phospholipon 90 G [containing 93% phosphatidylcholine (PC)] was initially dissolved in chloroform. The solvent was removed by evaporation under nitrogen in tubes to which labeled Ris was added to come to a final PC-Ris formulation at a weight ratio of 1 part Phospholipon 90G: 1 part risedronate.


\* Indicates  $p < 0.05$  vs Ris



# Comparison of the Bioavailability of Risedronate and PC-Risedronate in Rats

8-15+8-22-02





## Bioavailability of C<sup>14</sup>- Risedronate Alone and in Association with PC in Rats Dosed Before and After Feeding

Dose/rat=11.89 x 10<sup>6</sup> ± 0.24

Risedronate-rats fed immediately after dosing (CPM/ml plasma)

<u>Time</u> (hours)	0.5	1	2	4	8	24
	441	229	861	457	87	152
	962	467	458	437	113	82
	18,436	532	894	377	197	43
	534	552	697	324	99	115
	159	4216	157	213	-----	122
	837	1073	945	10648	188	40
	462	795	1135	4985	200	144
	<u>970</u>	<u>273</u>	<u>1493</u>	<u>656</u>	<u>100</u>	<u>197</u>
	2849.9	1016.8	830.2	2811.8	140.3	111.7
	±2228.9	±467.1	±144	±1325.6	±18.2	±19.3

Risedronate:PC-rats fed immediately after dosing (CPM/ml plasma)

<u>Time</u> (hours)	0.5	1	2	4	8	24
	1291	6205	1492	410	134	303
	520	13350	11724	863	192	261
	4463	943	5561	1750	1959	99
	1321	10217	3689	806	354	163
	2132	283	2560	10746	188	115
	1447	393	510	539	119	141
	720	642	1152	636	143	64
	<u>14007</u>	<u>419</u>	<u>5358</u>	<u>214</u>	<u>59</u>	<u>51</u>
	3237.5	4056.3	4005.5	1995.5	393.2	149.5
	±1598.6	±1847.7	±1286.6	±1260.6	±225.7	±32



**Risedronate-rats fed 30 minutes before dosing (CPM/ml plasma)**

<u>Time</u> (hours)	0.5	1	2	4	8	24
	1605	201	575	155	334	35
	316	1315	446	141	164	19
	486	3618	753	129	181	19
	1291	793	517	162	116	14
	334	450	3285	410	5176	128
	420	404	558	185	211	48
	413	270	647	323	207	44
	<u>538</u>	<u>1194</u>	<u>347</u>	<u>288</u>	<u>261</u>	<u>36</u>
	675.4	1029.5	891	224.1	831.3	42.7
	±173.1	±159.1	±343.2	±36.5	±621.1	±4.3

**Risedronate:PC- rats fed 30 minutes before dosing (CPM/ml plasma)**

<u>Time</u> (hours)	0.5	1	2	4	8	24
	3479	256	300	261	248	40
	447	180	444	639	201	56
	9917	1849	2004	400	146	59
	2711	273	336	377	229	63
	315	243	450	427	171	71
	2823	271	581	267	295	71
	260	3412	522	498	154	48
	<u>470</u>	<u>218</u>	<u>456</u>	<u>349</u>	<u>214</u>	<u>43</u>
	2552.8	837.8	636.7	402.3	207.3	56.4
	±1151.3	± 418.3	±198	±43.9	±17.9	±4.3

# **Bioavailability of C<sup>14</sup> - Risedronate Alone and in Association with PC in Rats Dosed Before and After Feeding**

